Novel cancer therapies have emerged over the past 10-15 years with high rates of cutaneous side effects, leading to increased demand for specialists in oncodermatology. These subspecialists have expertise in managing therapeutic complications, cutaneous metastases, and proactive management of potential adverse events. In this episode, CANCER BUZZ TV speaks with guest Meghan Heberton, MD, director of Oncodermatology and assistant professor of Dermatology at UT Southwestern Medical Center – Harold C. Simmons Comprehensive Cancer Center in Dallas, Texas. Dr. Heberton built the oncodermatology program at her cancer center and shares insights on the importance of collaboration across the multidisciplinary team. In developing a holistic care plan for each patient, Dr. Heberton sheds light on issues of access for patients with cancer seeking dermatologic expertise.   “I love communication…I think that direct communication breeds familiarity and also collegiality—it allows for us working together. Maybe you [as a clinician] see a pattern that you never saw before because you’re actually directly talking to the person who’s taking care of that patient in a different way.”—Meghan Heberton Meghan Heberton, MD  Director, Oncodermatology  Assistant Professor of Dermatology  UT Southwestern Medical Center – Harold C. Simmons Comprehensive Cancer Center  Dallas, TX    This video podcast was made possible with support from Johnson & Johnson. Resources ACCC Supportive Care Strategies for Dermatologic Toxicities Related to Cancer Therapies education program  Targeted Therapy Side Effects – American Cancer Society   Oncodermatology: Advancing the Science and Care of Cancer Patients and Survivors – National Institutes of Health PubMed Central